Zyklophin
Systematic (IUPAC) name | |
---|---|
N-Benzyl-L-tyrosylglycylglycyl-N-[(3S,6S,9S,12S)-6-[(2S)-2-butanyl]-3-({(2S)-5-carbamimidamido-1-[(2S)-2-{[(2S)-1,6-diamino-1-oxo-2-hexanyl]carbamoyl}-1-pyrrolidinyl]-1-oxo-2-pentanyl}carbamoyl)-9-(3-carbamimidamidopropyl)-5,8,11,14-tetraoxo-1,4,7,10-tetraazacyclotetradecan-12-yl]-L-phenylalaninamide | |
Clinical data | |
Legal status |
|
Identifiers | |
ATC code | None |
PubChem | CID 45483651 |
ChemSpider | 30844961 |
Chemical data | |
Formula | C65H96N20O13 |
Molar mass | 1365.584 g/mol |
| |
|
Zyklophin is a semisynthetic peptide derived from dynorphin A and a highly selective antagonist of the κ-opioid receptor (KOR).[1][2] It is systemically-active, displaying good metabolic stability and blood-brain-barrier penetration.[2] Similarly to other KOR antagonists, it has been shown to block stress-induced reinstatement of cocaine-seeking in animals.[2]
See also
References
- ↑ Patkar KA, Yan X, Murray TF, Aldrich JV (July 2005). "[Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist". J. Med. Chem. 48 (14): 4500–3. doi:10.1021/jm050105i. PMID 15999987.
- 1 2 3 Aldrich JV, Patkar KA, McLaughlin JP (October 2009). "Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action". Proc. Natl. Acad. Sci. U.S.A. 106 (43): 18396–401. doi:10.1073/pnas.0910180106. PMC 2775281. PMID 19841255.
This article is issued from Wikipedia - version of the Monday, April 13, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.